Antares Pharma (Nasdaq: ATRS) reported earnings on Nov. 7. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Antares Pharma beat slightly on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue increased significantly and GAAP loss per share increased.

Margins shrank across the board.

Revenue details
Antares Pharma reported revenue of $5.7 million. The three analysts polled by S&P Capital IQ expected to see a top line of $5.6 million on the same basis. GAAP reported sales were 45% higher than the prior-year quarter's $3.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at -$0.03. The one earnings estimate compiled by S&P Capital IQ predicted -$0.03 per share. GAAP EPS were -$0.03 for Q3 compared to -$0.01 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 42.0%, 1,190 basis points worse than the prior-year quarter. Operating margin was -61.9%, 2,960 basis points worse than the prior-year quarter. Net margin was -62.2%, 2,900 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $6.4 million. On the bottom line, the average EPS estimate is -$0.03.

Next year's average estimate for revenue is $23.5 million. The average EPS estimate is -$0.08.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 177 members out of 191 rating the stock outperform, and 14 members rating it underperform. Among 21 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 16 give Antares Pharma a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Antares Pharma is buy, with an average price target of $5.00.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.